Meta AnalysisID 7323
低剂量阿托品预防近视进展的疗效与安全性：随机临床试验的系统评价与Meta分析
CRD42023403622
To evaluate the efficacy and safety profile of low-dose (0.01%) atropine eye drops used for controlling myopia progression.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7323
- Evidence Id
- 15881
- Core Evidence Id
- 15881
- Source Meta Analysis Id
- 7311
- Herb2 Meta Analysis Id
- HBMA007311
- Crd Id
- CRD42023403622
- Title
- Efficacy and Safety of Low Dose Atropine for Preventing Myopia Progression: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Review Question
- To evaluate the efficacy and safety profile of low-dose (0.01%) atropine eye drops used for controlling myopia progression.
- Study Type Included
- Inclusion: randomized clinical trials (RCTs) Exclusion: (1) other types of original research (i.e., non-RCTs, cohort, and case-control) (2) non-original research (i.e., reviews, commentaries, guidelines, editorials, correspondence, letters to editors, etc.), (3) unavailable full-texts, (4) duplicated records or records with overlapping datasets
- Condition Being Studied
- Myopia is a relatively prevalent and increasing public health concern, particularly in East Asia, where it has already reached a pandemic level. An estimated 2.5 billion people will be affected by myopia in 2020. The prevalence has been reported to be 80% or higher in the young adult population in certain Asian countries or areas, such as Singapore, Hong Kong, and Taiwan. Similarly, in the United States, the prevalence of myopia is 20% to 50% among the population older than 12 years. This silent epidemic should not be ignored. The worldwide prevalence of myopia and high myopia is estimated to increase substantially, affecting nearly 5 billion and 1 billion people, respectively, by 2050. In addition, the cost of uncorrected refractive error is a very real existing problem, affecting as many as 88% of children with myopia, and thus, the implications of increasing myopia prevalence worldwide are significant. Apart from the substantial socioeconomic cost, severe sight-threatening complications associated with high myopia substantially compromise the quality of life.
- Participant
- Patients (<18 years old) with myopic refractive error
- Animal
- Human Disease Modelled
- Intervention
- Inclusion: low dose (0.01%) atropine eye drops Exclusion: (1) eye drops other than atropine (2) other doses of atropine eye drops (>0.01%)
- Comparator Control
- No restrictions applied
- Main Outcome
- • Primary outcomes: (1) Efficacy: We considered the weighted mean difference (WMD) and 95% CIs for low-dose (0.01%) atropine in refractive changes and axial elongation vs the control group. An effect size would be defined as small at 0.20 or greater, medium at 0.50 or greater, or large at 0.80 or greater, which means the treatment effect was low, moderate, or strong, respectively. (2) Safety: We’ll report the risk ratio for adverse effects between low-dose atropine and control groups. Measures of effect Pooled effect size (ES) along with its corresponding 95% confidence interval
- Outcome Measure
- Additional Outcome
- We’ll run a subgroup analysis on the difference in the effect size based on the gender, race, myopia grades (low, high, pathologic) and age group range (if applicable) Measures of effect Pooled effect size (ES) along with its corresponding 95% confidence interval
- Study Method
- Intervention, Meta-analysis, Prevention, Systematic review
- Keyword
- Humans
- Contact
- Hashem Abu Serhan [email protected]
- Organisational Affiliation
- Hamad Medical Corporations
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Qatar
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-02-28
- Registration Date
- 2023-03-10
- Anticipated Start Date
- 2023-03-01
- Anticipated Completion Date
- 2023-06-01
- Title Cn
- 低剂量阿托品预防近视进展的疗效与安全性：随机临床试验的系统评价与Meta分析
- Title En
- Efficacy and Safety of Low Dose Atropine for Preventing Myopia Progression: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Bilingual Status
- complete